BiomX Raises $7.5M Via Equity After Data From Lung Infection Candidate, Shares Fall

  • BiomX Inc PHGE announced results from Part 1 of the Phase 1b/2a trial evaluating the company's novel phage cocktail, BX004, for chronic pulmonary infections caused by Pseudomonas aeruginosa (or P. aeruginosa) in patients with cystic fibrosis ("CF").
  • No safety events related to treatment with BX004
  • Mean P. aeruginosa colony forming units (CFU) at Day 15 (compared to baseline): -1.42 log10 CFU/g (BX004) vs. -0.28 log10 CFU/g (placebo). This reduction was seen on top of standard-of-care inhaled antibiotics.
  • Phages were detected in all patients treated with BX004; no phages were detected in patients receiving a placebo.
  • There was no emerging resistance to BX004 during or after treatment with BX004.
  • As expected, likely due to the short course of therapy, there was no detectable effect on % predicted FEV1
  • Part 2 of the Phase 1b/2a study of BX004 will evaluate the safety and efficacy of BX004 in 24 CF patients. Data are expected in Q3 of 2023.
  • Concurrently, the company announced a private placement of 30.6 million shares at $0.245 per share, with gross proceeds of approximately $7.5 million.
  • Price Action: PHGE shares are down 9.77% at $0.31 on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!